4//SEC Filing
Kwan Pui San 4
Accession 0001209191-21-015496
CIK 0001340652other
Filed
Feb 28, 7:00 PM ET
Accepted
Mar 1, 8:54 PM ET
Size
20.9 KB
Accession
0001209191-21-015496
Insider Transaction Report
Form 4
Kwan Pui San
Principal Acctg Officer
Transactions
- Award
Stock Option (right to buy)
2021-02-25+16,640→ 16,640 totalExercise: $65.87Exp: 2031-02-25→ Common Stock (16,640 underlying) - Exercise/Conversion
Common Stock
2021-03-01$9.04/sh+833$7,530→ 6,579 total - Exercise/Conversion
Common Stock
2021-03-01$10.86/sh+1,389$15,085→ 4,621 total - Exercise/Conversion
Common Stock
2021-03-01$11.02/sh+1,125$12,398→ 5,746 total - Sale
Common Stock
2021-03-01$68.08/sh−1,530$104,169→ 5,049 total - Exercise/Conversion
Stock Option (right to buy)
2021-03-01−1,389→ 13,897 totalExercise: $10.86Exp: 2028-03-05→ Common Stock (1,389 underlying) - Sale
Common Stock
2021-03-01$68.89/sh−1,817$125,166→ 3,232 total - Exercise/Conversion
Stock Option (right to buy)
2021-03-01−1,125→ 24,750 totalExercise: $11.02Exp: 2029-03-04→ Common Stock (1,125 underlying) - Exercise/Conversion
Stock Option (right to buy)
2021-03-01−833→ 25,834 totalExercise: $9.04Exp: 2029-11-01→ Common Stock (833 underlying)
Footnotes (6)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F2]Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $67.64 to $68.60 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- [F3]Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $68.64 to $69.19 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- [F4]The option was granted on February 25, 2021, and 25% of the total number of shares of common stock subject to the option vests on January 1, 2022, and 1/48th of the total number of shares of common stock subject to the option vests monthly thereafter, subject to the Reporting Person's continued service to the Company on each such vesting date.
- [F5]Not applicable.
- [F6]As of March 1, 2021, and prior to this transaction, the exercised options were fully vested.
Documents
Issuer
ChemoCentryx, Inc.
CIK 0001340652
Entity typeother
Related Parties
1- filerCIK 0001733642
Filing Metadata
- Form type
- 4
- Filed
- Feb 28, 7:00 PM ET
- Accepted
- Mar 1, 8:54 PM ET
- Size
- 20.9 KB